REBEKAH HELMIG: Open Payments
NPI 1851803159 · SAINT CLAIR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,623 in 162 payments from 22 companies in 2025. Trend: 2023 $2,788 · 2024 $1,916 · 2025 $2,623
Food & beverage: $2,490Education: $134
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $625 |
| AstraZeneca Pharmaceuticals LP | 8 | $240 |
| Lilly USA, LLC | 10 | $196 |
| Novo Nordisk Inc | 15 | $195 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $161 |
| Amgen Inc. | 18 | $155 |
| Lundbeck LLC | 9 | $155 |
| PFIZER INC. | 15 | $154 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $145 |
| SANOFI-AVENTIS U.S. LLC | 3 | $93 |
Products named: REXULTI, VRAYLAR, QULIPTA, AIRSUPRA, MOUNJARO, CAPLYTA, UBRELVY, XIFAXAN.
Industry payments across MO — which companies pay providers there.
